Monday, September 22, 1997
OXFORD - Britain's biotech sector has been given a welcome if modest
boost with the news that Scotia Holdings (LSE:SOH) has signed licensing deals worth
potentially in excess of $100 million.
SOH (Stirling, U.K.) signed licensing agreements with Boehringer
Ingelheim and Kyowa Hakko Kogyo for the development and commercialization of Foscan, its
photodynamic therapy (PDT) agent for cancer and pre-malignant conditions.